Evidence map›Paper›PMID 30642285›Full record

Trial reportBMC cancer2019

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.

Perrin E Romine, Renato G Martins, Keith D Eaton, Douglas E Wood, Fatemeh Behnia, Bernardo H L Goulart, Michael S Mulligan, Sarah G Wallace, Elizabeth Kell, Julie E Bauman and 2 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00227539 (Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00227539 phase2completednot on this map

Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer

TypeinterventionalSponsorUniversity of WashingtonRan2005 to 2013Enrolled25ConditionsLung CancerArmscisplatin, pemetrexed disodium, adjuvant therapy, therapeutic conventional surgery, fludeoxyglucose F 18
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Annals of translational medicine · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Perrin E RomineUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Renato G MartinsUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Keith D EatonUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA. kdeaton@u.washington.edu.
Douglas E WoodUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Fatemeh BehniaUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Bernardo H L GoulartUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Michael S MulliganUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Sarah G WallaceUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Elizabeth KellSeattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA, 98109, USA.
Julie E BaumanUniversity of Arizona, Tucson, AZ, USA.
Shilpen A PatelGrail Inc., Menlo Park, CA, USA.
Hubert J VesselleUniversity of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.

Funding

WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6M
Eli Lilly and Company Grant number H3E-US-X043NCI NIH HHS P50 CA097190
6 · The paper itself

Abstract

backgroundNeoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value after one cycle of induction chemotherapy.

methodsIn this phase II non-randomized trial, patients with AJCC version 6 stage IB to IIIB operable NSCLC were treated with 3 cycles of cisplatin and pemetrexed neoadjuvant chemotherapy. Patients underwent FDG-PET scanning prior to and 18 to 21 days after the first cycle of chemotherapy. Investigators caring for patients were blinded to results, unless the scans showed evidence of disease progression. FDG-PET response was defined prospectively as a ≥ 20% decrease in the SUV of the primary lesion.

resultsBetween October 2005 and February 2010, 25 patients enrolled. Fifty two percent were female, 88% white, and median age was 62 years. Histology was divided into adenocarcinoma 66%, not otherwise specified (NOS) 16%, squamous cell 12%, and large cell 4%. Stage distribution was: 16% IB, 4% IIB, and 79% IIIA. Treatment was well tolerated and only one patient had a grade 4 toxicity. The median follow up was 95 months. The 5 year progression free survival (PFS) and overall survival (OS) for the entire population were 54 and 67%, respectively. Eighteen patients had a baseline FDG-PET scan and a repeat scan at day 18-21 available for comparison. Ten patients (56%) were considered metabolic responders on the day 18-21 FDG-PET scan. Responders had a 5 year PFS and OS of 60 and 70%, respectively, while the percentage for non-responders was 63 and 75% (p = 0.96 and 0.85).

conclusionsThis phase II trial did not demonstrate that a PET scan after one cycle of chemotherapy can predict survival outcomes of patients with NSCLC treated with neoadjuvant chemotherapy.

trial registrationNCT00227539 registered September 28th, 2005.

Indexed as

Positron-Emission TomographyAdultAgedCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDisease ProgressionFemaleFluorodeoxyglucose F18HumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingFluorodeoxyglucose F18(18F)-FDG PETNeoadjuvant chemotherapyNon-small cell lung cancer

Identifiers

PMID30642285
PMCPMC6332837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.